Fig. 1

Fig. 2



Fig. 3

Fig. 4



Fig. 5

Fig. 5a

Fig. 5b

Fig. 5c



Fig. 5d

Fig. 5e

Fig. 5f

Fig. 6


Apoptotic Jurkat cells (%)
30
25
20
15
10
5
0
Control
MPR
TEN
TEN + NOK1
Skin sample

Fig. 7



Fig. 7a

Fig. 7b

Fig. 8


no IVIG
IVIG
Albumin
150
100
50
0
Viability (%)
HEK
HaCaT
HepG2
A20
A20R
rhsFasL

Fig. 9



Fig. 9a

Fig. 9b

Fig. 10


Fas
TNFR1
Alb.
Fas
TNFR1
Alb.
Fas
TNFR1
Alb.
kD
200
100
50
IVIG
anti-Fas
Ponceau

Fig. 11


rhsFasL (2.5 ng/ml)
Viability
(% of control cells)
80
60
40
20
0
Vehicle
IVIG
Fas-Fc immuno-adsorbed IVIG
TRAILR2-Fc immuno-adsorbed IVIG

Mauri, French and Tschopp, Figure 1

Fig. 12A.



Fig. 12B.

	WB	WB
IVIG	Comp	Fas-Comp
98J30AB12	Negative	Positive
99A18AB11	Negative	Positive
98K13AB12	Negative	Positive
2620M081A	Negative	Positive
99A13AB11	Negative	Positive
2453397F	Negative	Positive
2456898I	Negative	Positive
2470797G	Negative	Positive
2454198F	Negative	Positive
2470597G	Negative	Positive
Sandoglobulin	Negative	Positive
Anti-Fas Apo1	Negative	Positive
Vehicle	Negative	Negative

A.



B.

IVIG	FasL ELISA Inhibition % Max at 30 mg/ml	Categories
98J30AB12	45	2
99A18AB11	49	2
98K13AB12	49	2
2620M081A	60	Best
99A13AB11	44	2
2453397F	26	Worst
2456898I	36	3
2470797G	39	3
2454198F	45	2
2470597G	48	2
Sandoglobulin	35	3
Vehicle	100% binding	
	1 hr Preincubation	

C.



Fig. 14A.



Fig. 14B.

IVIG	FasL Killing Inhibition Start mg/ml	FasL Killing Inhibition Peak mg/ml	Categories
98J30AB12	0.5	4	2
99A18AB11	1	8	3
98K13AB12	1	8	3
2620M081A	2	8	4
99A13AB11	1	15	4
2453397F	1	4	2
2456898I	1	4	2
2470797G	1	4	2
2454198F	0.25	8	Best
2470597G	0.25	8	Best
Sandoglobulin	15	30	Worst
Vehicle	Negative	Negative	
	No Preincubation	No Preincubation	

Fig. 14C.





Mme. N. A. (1958) GVHD

IVIG



Fig. 15A

Anti-Fas certified IVIG



Fig. 15B

Anti-Fas certified IVIG